Location History:
- Suita, JP (2007 - 2008)
- Ibaraki, JP (2012 - 2016)
- Osaka, JP (2018)
Company Filing History:
Years Active: 2007-2018
Title: Yasushi Ochiai: Innovator in Ophthalmic Formulations and Drug Delivery Systems
Introduction
Yasushi Ochiai is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in ophthalmic formulations and drug delivery systems. With a total of 8 patents to his name, his work has had a considerable impact on medical treatments.
Latest Patents
Among his latest patents is an ophthalmic suspension formulation that comprises (R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2′,3,5′-tetrone. This formulation is designed to treat diseases in the posterior eye segment while minimizing side effects associated with systemic exposure. Another significant patent is for press-coated orally-disintegrating tablets. This invention aims to provide a tablet with an inner core that has poor formability but excellent disintegrability and suitable hardness. The outer layer of the tablet consists of microcrystalline cellulose, a sugar or sugar alcohol, and specific ingredients like crospovidone and starches.
Career Highlights
Yasushi Ochiai has worked with prominent companies in the pharmaceutical industry, including Sumitomo Dainippon Pharma Co., Ltd. and Dainippon Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to develop innovative solutions that address critical medical needs.
Collaborations
Throughout his career, Yasushi has collaborated with talented individuals such as Yuki Ikeda and Kouji Wakisaka. These partnerships have contributed to the advancement of his research and the successful development of his inventions.
Conclusion
Yasushi Ochiai is a distinguished inventor whose work in ophthalmic formulations and drug delivery systems has made a significant impact in the pharmaceutical field. His innovative patents and collaborations highlight his commitment to improving medical treatments.